# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $18 ...
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0...
JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the price targe...
Leerink Partners analyst Joseph Schwartz upgrades Solid Biosciences (NASDAQ:SLDB) from Market Perform to Outperform and main...
Piper Sandler analyst Biren Amin reiterates Solid Biosciences (NASDAQ:SLDB) with a Overweight and maintains $20 price target.